Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 3 4Phase 2 2

Status

Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 4Genitourinary 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Neuroendocrine Prostate Cancer 1Extensive Stage Small Cell Lung Cancer 1Bites and Stings 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × AMG 757 × Clear all
NCT06598306 2026-05-29

DeLLphi-308

Amgen

Phase 1 Recruiting
220 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT07037758 2026-05-29

DeLLphi-311

Amgen

Phase 1 Recruiting
380 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

NCT04885998 2025-09-29

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Amgen

Phase 1 Completed
23 enrolled 21 charts
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04702737 2025-09-12

DeLLpro-300

Amgen

Phase 1 Completed
41 enrolled 19 charts
EndocrineGenitourinary

Neuroendocrine Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡